These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17202834)

  • 1. Efficient amplification of melanoma-specific CD8+ T cells using artificial antigen presenting complex.
    Chang J
    Exp Mol Med; 2006 Dec; 38(6):591-8. PubMed ID: 17202834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
    Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
    Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.
    Lu X; Jiang X; Liu R; Zhao H; Liang Z
    Cancer Lett; 2008 Nov; 271(1):129-39. PubMed ID: 18621475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
    Dupont J; Latouche JB; Ma C; Sadelain M
    Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.
    Latouche JB; Sadelain M
    Nat Biotechnol; 2000 Apr; 18(4):405-9. PubMed ID: 10748520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses.
    Yu X; He J; Mongkhoune S; Peng Y; Xie Y; Su J; Zhou SF; Xie XX; Luo GR; Fang Y; Li X; Li X; Zhou N; Zhao YX; Lu XL
    Asian Pac J Trop Med; 2013 Jun; 6(6):467-72. PubMed ID: 23711708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Activation of specific T lymphocyte induced by artificial antigen presenting cell complex in vitro].
    Mao HW; Liu WL; Zhou JF; Geng Z; Huang W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):655-8. PubMed ID: 18549648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.
    Oelke M; Maus MV; Didiano D; June CH; Mackensen A; Schneck JP
    Nat Med; 2003 May; 9(5):619-24. PubMed ID: 12704385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
    Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
    Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of tumor antigen-specific cytotoxic T cell responses in naïve mice by latex microspheres-based artificial antigen-presenting cell constructs.
    Shen C; Zhang J; Xia L; Meng F; Xie W
    Cell Immunol; 2007 May; 247(1):28-35. PubMed ID: 17720150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
    Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
    Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
    Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction.
    Schilbach K; Kerst G; Walter S; Eyrich M; Wernet D; Handgretinger R; Xie W; Rammensee HG; Müller I; Bühring HJ; Niethammer D
    Blood; 2005 Jul; 106(1):144-9. PubMed ID: 15731181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basophils can directly present or cross-present antigen to CD8 lymphocytes and alter CD8 T cell differentiation into IL-10-producing phenotypes.
    Kim S; Shen T; Min B
    J Immunol; 2009 Sep; 183(5):3033-9. PubMed ID: 19667092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective immunity from naive CD8+ T cells activated in vitro with MHC class I binding immunogenic peptides and IL-2 in the absence of specialized APCs.
    Hauser C; Zipprich F; Leblond I; Wirth S; Hügin AW
    J Immunol; 1999 Jul; 163(1):330-6. PubMed ID: 10384132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
    Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
    J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
    Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
    Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.
    Maus MV; Thomas AK; Leonard DG; Allman D; Addya K; Schlienger K; Riley JL; June CH
    Nat Biotechnol; 2002 Feb; 20(2):143-8. PubMed ID: 11821859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.